Introgen's Data-Mining Misleads

My critique last Saturday of Introgen Therapeutics(INGN Quote) sparked some sharp negative reaction by readers, mainly from those believing strongly in the potential of the company's Advexin cancer drug.

So let's take a closer look at the available data and, as a related byproduct, the difference between clinical data that are collected and analyzed prospectively vs. the same done retrospectively.

It's an important distinction that has a big impact on the quality of data and the subsequent conclusions you can make. This issue comes up often in biotech investing, so it's a good topic to explore that's applicable well beyond Introgen. ...